S&P 500   4,285.75 (+0.27%)
DOW   33,964.85 (-0.05%)
QQQ   330.16 (+0.51%)
AAPL   174.59 (+0.02%)
MSFT   291.53 (+0.07%)
META   175.54 (+0.39%)
GOOGL   120.70 (+0.96%)
AMZN   142.67 (+0.40%)
TSLA   917.05 (+0.55%)
NVDA   188.01 (+2.54%)
NIO   19.96 (-0.60%)
BABA   90.78 (+1.13%)
AMD   100.58 (+2.35%)
MU   63.01 (+2.26%)
T   18.46 (+0.22%)
CGC   3.88 (-4.43%)
F   16.06 (+0.19%)
GE   79.58 (-0.43%)
DIS   122.87 (+0.05%)
AMC   20.08 (-5.99%)
PYPL   98.92 (-0.50%)
PFE   49.06 (-0.43%)
NFLX   245.44 (+1.78%)
S&P 500   4,285.75 (+0.27%)
DOW   33,964.85 (-0.05%)
QQQ   330.16 (+0.51%)
AAPL   174.59 (+0.02%)
MSFT   291.53 (+0.07%)
META   175.54 (+0.39%)
GOOGL   120.70 (+0.96%)
AMZN   142.67 (+0.40%)
TSLA   917.05 (+0.55%)
NVDA   188.01 (+2.54%)
NIO   19.96 (-0.60%)
BABA   90.78 (+1.13%)
AMD   100.58 (+2.35%)
MU   63.01 (+2.26%)
T   18.46 (+0.22%)
CGC   3.88 (-4.43%)
F   16.06 (+0.19%)
GE   79.58 (-0.43%)
DIS   122.87 (+0.05%)
AMC   20.08 (-5.99%)
PYPL   98.92 (-0.50%)
PFE   49.06 (-0.43%)
NFLX   245.44 (+1.78%)
S&P 500   4,285.75 (+0.27%)
DOW   33,964.85 (-0.05%)
QQQ   330.16 (+0.51%)
AAPL   174.59 (+0.02%)
MSFT   291.53 (+0.07%)
META   175.54 (+0.39%)
GOOGL   120.70 (+0.96%)
AMZN   142.67 (+0.40%)
TSLA   917.05 (+0.55%)
NVDA   188.01 (+2.54%)
NIO   19.96 (-0.60%)
BABA   90.78 (+1.13%)
AMD   100.58 (+2.35%)
MU   63.01 (+2.26%)
T   18.46 (+0.22%)
CGC   3.88 (-4.43%)
F   16.06 (+0.19%)
GE   79.58 (-0.43%)
DIS   122.87 (+0.05%)
AMC   20.08 (-5.99%)
PYPL   98.92 (-0.50%)
PFE   49.06 (-0.43%)
NFLX   245.44 (+1.78%)
S&P 500   4,285.75 (+0.27%)
DOW   33,964.85 (-0.05%)
QQQ   330.16 (+0.51%)
AAPL   174.59 (+0.02%)
MSFT   291.53 (+0.07%)
META   175.54 (+0.39%)
GOOGL   120.70 (+0.96%)
AMZN   142.67 (+0.40%)
TSLA   917.05 (+0.55%)
NVDA   188.01 (+2.54%)
NIO   19.96 (-0.60%)
BABA   90.78 (+1.13%)
AMD   100.58 (+2.35%)
MU   63.01 (+2.26%)
T   18.46 (+0.22%)
CGC   3.88 (-4.43%)
F   16.06 (+0.19%)
GE   79.58 (-0.43%)
DIS   122.87 (+0.05%)
AMC   20.08 (-5.99%)
PYPL   98.92 (-0.50%)
PFE   49.06 (-0.43%)
NFLX   245.44 (+1.78%)
OTCMKTS:EPRSQ

EPIRUS Biopharmaceuticals - EPRSQ Stock Forecast, Price & News

Add
Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
25 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About EPIRUS Biopharmaceuticals

EPIRUS Biopharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. Its lead product candidate is BOW015, a biosimilar version of Remicade (infliximab) for the treatment of various inflammatory diseases. The company's pipeline of biosimilar product candidates also include BOW050, a biosimilar version of Humira (adalimumab) to treat inflammatory diseases, including rheumatoid arthritis and various other forms of adult and pediatric arthritis, ankylosing spondylitis, inflammatory bowel disease, and chronic psoriasis and psoriasis; and BOW070, a biosimilar version of Actemra (tocilizumab) for the treatment of rheumatoid arthritis, polyarticular arthritis, and systemic juvenile idiopathic arthritis. In addition, it is developing BOW080, a biosimilar version of Soliris for the treatment of ultra-rare blood disorders, including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and BOW100, a biosimilar version of SIMPONI for the treatment of inflammatory diseases, including rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, and psoriatic arthritis. The company has a license agreement with Sun Pharmaceutical Industries Ltd.; license and collaboration agreement with Livzon Mabpharm Inc.; and collaboration agreement with Polpharma S.A. The company was founded in 2011 and is headquartered in Boston, Massachusetts. On July 25, 2016, Epirus Biopharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Massachusetts.

Receive EPRSQ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for EPIRUS Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

EPRSQ Stock News Headlines

Epirus Biopharmaceuticals Inc (EPRSQ)
EPIRUS Biopharmaceuticals Inc.
EPIRUS Biopharmaceuticals Inc
See More Headlines

Receive EPRSQ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for EPIRUS Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

EPRSQ Company Calendar

Last Earnings
8/20/2014
Today
8/18/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:EPRSQ
Previous Symbol
NASDAQ:EPRS
Employees
73
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
5.26

Key Executives

  • Mr. Jeff Kagy
    VP of HR & Admin.
  • Jason Yap
    Head of Global Regulatory Affairs and Sr. Director
  • Dr. Louis Boon
    Head of CLG, Bioassay & Process Devel.
  • Emile Van Corven Ph.D.
    Head of Analytical Devel. and Downstream PD
  • Dr. Bram Bout Ph.D.
    Head of Epirus (Netherlands) B.V.













EPRSQ Stock - Frequently Asked Questions

How were EPIRUS Biopharmaceuticals' earnings last quarter?

EPIRUS Biopharmaceuticals, Inc. (OTCMKTS:EPRSQ) announced its earnings results on Wednesday, August, 20th. The biopharmaceutical company reported ($1.52) earnings per share for the quarter, missing the consensus estimate of ($1.20) by $0.32.

What is EPIRUS Biopharmaceuticals' stock symbol?

EPIRUS Biopharmaceuticals trades on the OTCMKTS under the ticker symbol "EPRSQ."

How do I buy shares of EPIRUS Biopharmaceuticals?

Shares of EPRSQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

How can I contact EPIRUS Biopharmaceuticals?

EPIRUS Biopharmaceuticals' mailing address is 699 BOYLSTON ST 8TH FLOOR, BOSTON MA, 02116. The official website for the company is www.epirusbiopharma.com. The biopharmaceutical company can be reached via phone at (617) 600-3497, via email at tshea@epirusbiopharma.com, or via fax at 617-301-7010.

This page (OTCMKTS:EPRSQ) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.